tradingkey.logo

Medpace Holdings Inc

MEDP
View Detailed Chart

490.640USD

-6.950-1.40%
Close 09/12, 16:00ETQuotes delayed by 15 min
13.75BMarket Cap
32.86P/E TTM

Medpace Holdings Inc

490.640

-6.950-1.40%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.40%

5 Days

+0.75%

1 Month

+4.84%

6 Months

+54.32%

Year to Date

+47.68%

1 Year

+39.52%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-12

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
14 / 507
Overall Ranking
132 / 4724
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 12 analysts
Hold
Current Rating
424.837
Target Price
-13.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 44.46% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 64.90.
Overvalued
The company’s latest PE is 35.47, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.22M shares, decreasing 4.83% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.38M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.05.

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Ticker SymbolMEDP
CompanyMedpace Holdings Inc
CEODr. August J. Troendle, M.D.
Websitehttps://investor.medpace.com/
KeyAI